Pro-urokinase for Extended-Window Posterior Circulation Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 586 participants.

Also called NCT07617870

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 586 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07617870
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07617870. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pro-urokinase for Extended-Window Posterior Circulation Stroke
Acronym
PROMISE
Condition
Acute Ischemic Stroke
Intervention (Drug)
rhPro-UK
Intervention (Drug)
placebo
Intervention (Drug)
Aspirin
Intervention (Drug)
Placebo
Lead sponsor
The First Affiliated Hospital of Zhengzhou University (class: other)

Record details

Record id
cardio:ct-nct07617870
Content hash
766d75041a5d964fd83ee9f827954b7fc51dcebd2b8afa807ad6b3dd84f48011